StopBleed Hemostatic Powder: How India’s Nano-Biopolymer Bleeding Control Technology Works

NewsWebFit – Health, Science, Nutrition & Wellness

When someone is badly injured, the minutes before professional care arrives can decide the outcome. Uncontrolled bleeding is widely described by trauma educators as the leading cause of preventable death after injury. India has a large burden of road-traffic trauma, and NIT Rourkela has pointed out that many accident deaths involve delays in controlling bleeding, often in places far from advanced hospitals.

Against this background, an Indian startup has drawn national attention. StopBleed hemostatic powder, made by Miraqules MedSolutions Private Limited, is a topical bleeding-control product built on technology developed at NIT Rourkela. This article explains what the product is, how hemostatic technology works in general, what the manufacturer claims, what independent evidence is available, and where the limits lie. Nothing here is a treatment recommendation.

Key Information at a Glance

Product: StopBleed®, a topical (external) hemostatic product described as a rapid nano-biopolymer hemostat.
Maker: Miraqules MedSolutions Pvt. Ltd., a spin-off of NIT Rourkela.
Formats on the official website: StopBleed Powder and StopBleed Pro (a pellet delivered by a pre-filled applicator).
Reported regulatory status: NIT Rourkela reported in February 2026 that CDSCO approved StopBleed as a Class C medical device.
Evidence status: Laboratory and animal testing and a first-in-human study are reported by the institute and company. No full clinical trial report was found in the sources reviewed.
Important: No hemostatic product replaces direct pressure, emergency care or hospital treatment.

What Is StopBleed®?

StopBleed® is a topical hemostatic agent. A hemostatic agent is a material placed on or in a bleeding wound to help blood form a clot. It is not a medicine you swallow or inject. According to NIT Rourkela, it is an advanced bleeding-control solution available in powder and pellet forms, intended for trauma situations such as road accidents, military injuries and emergency first aid. The institute also says it has a shelf life of three years at room temperature.

Miraqules describes StopBleed as its first patented product. On its own website, the company says it can stop post-traumatic bleeding in about 40 seconds. Pages from the same site use slightly different wording elsewhere, such as “less than a minute” or “within a minute”. These are manufacturer statements, and the conditions behind them are not spelled out on those pages. A later section returns to this.

The Indian Innovation Behind StopBleed

From an academic lab to a startup

NIT Rourkela says the technology was developed in its Department of Biotechnology and Medical Engineering by Professor Devendra Verma and his research student Sabir Hossain. The institute patented it and then transferred it to Miraqules MedSolutions, led by Dr Hossain, for manufacturing, distribution and field deployment. The company’s own team page says Mr Hossain completed an M.Tech in Biomedical Engineering at NIT Rourkela in 2018 and has served as CEO and co-founder since 2018. Professor Verma’s institutional CV also lists co-founding Miraqules in 2018 to commercialise StopBleed.

Is the company based in Bardhaman?

Partly, according to the company’s own pages. The registered address on the official website is in Burdwan (also spelled Bardhaman), West Bengal, PIN 713101. The same pages list an office and contact address in Bengaluru, Karnataka. A YourStory profile also describes Miraqules as a medtech startup from Burdwan. Readers should therefore treat Burdwan as the registered base, and should not assume all work happens there.

Patents

Patent records show that US patent 12,280,071 B2, titled “Self-assembled nano-fibers as hemostatic agent”, lists Devendra Verma and Sabir Hossain as inventors and NIT Rourkela as assignee. It was granted on 22 April 2025. NIT Rourkela adds that the product has patent protection in India, the USA, China, Australia and Israel. A patent shows that an invention is novel and documented. It does not show that a product is safe or effective in people.

How Does Hemostatic Technology Work?

How the body normally stops bleeding

Hemostasis is the body’s process for stopping blood loss from a damaged vessel. Medical references usually describe it in stages:

Vessel constriction: the injured blood vessel narrows to reduce flow.
Platelet plug: platelets stick to the damaged lining and to each other, forming a temporary, fragile plug.
Coagulation cascade: a chain of clotting factors, mostly made in the liver, switches on in sequence and produces thrombin.
Fibrin clot: thrombin converts fibrinogen into fibrin, which forms a mesh that is cross-linked and holds the platelets in place, giving a stable clot.

If any part of this system fails, bleeding can continue. Examples include clotting-factor deficiencies, platelet problems, or medicines that slow clotting. Very large injuries can also overwhelm the process, because the wound is simply too big for a small clot to seal.

Natural clotting vs hemostatic products

Natural clotting is the body’s own response. A hemostatic product does not replace it. Depending on the design, it may absorb fluid so clotting components become concentrated, act as a scaffold for clot formation, press against the bleeding site, or deliver clotting-related proteins. Which of these roles a product plays depends on its materials, and each design has its own strengths and limits.

The reported StopBleed mechanism

Miraqules’ technology page says its material is made as a fibrous matrix at room temperature, using electrostatic attraction between differently charged biomaterials. The company says this avoids chemical cross-linking agents that are used in some other fibre-making methods. It reports that the fibrous structure has a very large surface area compared with its volume and can absorb roughly 30 times its dry weight. The company says this quickly concentrates clotting factors at the wound. It also says the fibres carry a surface charge and form non-covalent bonds with red blood cells and platelets, which helps a stable clot form.

NIT Rourkela gives a similar summary: the nanofibrous material absorbs plasma and traps blood cells in a fine fibre mesh, which speeds up natural clotting and forms a strong hydrogel seal at the wound.

Published patent documents from the same inventors describe a composition of nanofibres, 20 to 200 nanometres in diameter, made from a negatively charged component (casein or its derivatives) combined with a positively charged one (chitosan or its derivatives). The company’s product label warns that the product contains a polysaccharide from shrimp shells, which is consistent with chitosan being a key ingredient. However, a complete public ingredient list for the commercial product was not found in the sources reviewed. The exact commercial formulation is therefore not independently verified.

Understanding the Different StopBleed Product Formats

The official Miraqules website lists two products: StopBleed Powder and StopBleed Pro. The product name “pellet” appears in the web address of the Pro page and in institutional news reports, which describe the range as powder and pellet forms.

StopBleed Powder

The manufacturer presents the powder as suited to irregular and complex wounds, because it can spread to fit the wound’s shape. It lists uses from minor cuts to deep wounds. These uses come from the manufacturer’s page, and the term “deep-seated wounds” should not be read as permission for untrained people to treat serious injuries at home.

StopBleed Pellet and StopBleed Pro

StopBleed Pro is described as a pellet delivered through a pre-filled applicator, designed for narrow entry wounds, with gunshot and stab wounds given as examples. Targeted delivery of this kind belongs in the setting of trauma care and trained responders. A narrow, deep wound can hide serious internal bleeding that no surface product can control.

StopBleed Gauze and Patches

The official product pages reviewed do not list a StopBleed gauze or patch. Miraqules’ technology page mentions other applications that are in concept or development, such as burn care, chronic wound care and anti-adhesion barriers, but these are not described as available products. Any gauze or patch version should therefore be treated as not independently verified until the company or a regulator confirms it.

Product Format	Intended Application	Delivery Form	Important Considerations
StopBleed Powder	Irregular or complex external wounds (manufacturer description)	Loose powder in a sealed bottle	Label says do not eat, avoid eyes, and do not rely on sterility if packaging is damaged. Should be used with the manufacturer’s instructions and medical care where needed.
StopBleed Pellet / StopBleed Pro	Narrow entry wounds such as stab or gunshot injuries (manufacturer description)	Pellet in a pre-filled applicator	Label warns against placing the product into blood vessels, citing risk of embolisation. Narrow penetrating injuries need urgent professional care.
StopBleed Gauze	Not independently verified	Not independently verified	Not listed on the official product pages reviewed.
StopBleed Patches	Not independently verified	Not independently verified	Not listed on the official product pages reviewed.

What Makes StopBleed Different?

Below are the main features the manufacturer highlights. They should be read as claims by the company, not as independently established facts.

Speed. The company says bleeding can be arrested in about 40 seconds, and that the powder stops bleeding five times faster than similar products. The company page does not name the comparator products, the test model or the measurement method. Without those details, “five times faster” cannot be interpreted. A claim of 30 seconds or less was not found on the official pages reviewed, so it is not independently verified.
Material technology. The room-temperature fabrication method, the fibrous structure and the high absorption capacity are described by the company and partly supported by patent filings and academic papers on related materials.
Heat. Some older hemostatic materials are known to produce heat when they absorb blood. Miraqules states that StopBleed causes no heat generation in the wound. This is a manufacturer claim and was not independently verified.
Removal. The company’s instructions describe washing the product out of the wound with saline or sterile water once bleeding stops, and removing the pellet and irrigating the wound after Pro use. Whether removal is straightforward in real emergencies has not been independently assessed.
Special conditions. The manufacturer says the product works in people with clotting disorders, in hypothermic blood, and in patients on blood thinners. It also says it prevents infections. These are strong claims. No independent clinical data supporting them were found in the sources reviewed, and readers should not assume any hemostatic product is guaranteed to work in every patient or to prevent infection.

What Does Scientific Evidence Say?

Medical claims are best judged by separating the type of evidence behind each one.

What is documented

Peer-reviewed laboratory research on related materials. A 2021 paper in Materials Today Communications (Hossain, Mohanty and Verma) studied nanofibrous aggregates made from chitosan and alginate. It reported that clot strength depended on the chitosan content, that the nanofibrous structure and high absorption appeared to explain the faster clotting, and that in-vivo studies suggested the fibres were safe and biocompatible. A 2021 paper in the International Journal of Biological Macromolecules (Mishra and colleagues, including Hossain and Verma) studied chitosan and casein nanofibres and reported that more chitosan gave faster clotting in laboratory and animal settings. These papers support the scientific idea behind the technology. They are not clinical trials of the commercial StopBleed product, and whether their formulations match the product as sold has not been verified.
Company-reported testing. Miraqules says it completed design verification and validation studies for safety and efficacy in mice, rabbits and pigs. NIT Rourkela says the team conducted laboratory and animal testing in line with ISO 10993 safety standards and USFDA guidelines, with satisfactory results. The full data were not found in public sources.
A first-in-human study. NIT Rourkela reports that StopBleed was tested in a real-life clinical setting through a first-in-human study with the Sanjay Gandhi Institute of Trauma and Orthopedics in Bangalore. A published paper or full results from this study were not found.

Regulatory status

NIT Rourkela and several trade and news outlets reported in February 2026 that CDSCO approved StopBleed as a Class C medical device for commercial manufacturing and clinical deployment. Reports add that Miraqules has started limited deployment in select clinical settings to learn how acceptable the product is as a standard of care for external bleeding. The CDSCO licence database was not consulted for this article, and licence numbers, approved indications and the exact scope covering each format are not independently verified. Readers who need this detail, such as hospitals or procurement teams, should ask the company for its licence documents and check them with CDSCO.

What still needs independent evidence: published comparative trials, defined test conditions for the speed claims, performance in patients on anticoagulants or with clotting disorders, long-term safety, and results from the first-in-human study.

Can StopBleed Help in Serious Injuries?

NIT Rourkela describes the intended use as rapid control of severe external bleeding from road accidents, gunshot injuries, blast injuries, industrial accidents, deep stab wounds and other life-threatening trauma, in the hands of medical professionals and non-medical first-aid responders. That is the intended role: a tool for external bleeding while the patient moves toward definitive care.

The limits are just as important. A topical product cannot repair a torn blood vessel, treat internal bleeding, replace lost blood, restore blood pressure or perform surgery. A person with serious injury still needs emergency medical assessment, and may need transfusion or an operation. A product, however advanced, never replaces these.

Safety, Limitations and Important Precautions

Call emergency services for severe bleeding

If bleeding is heavy, spurting, does not slow down, or follows a serious accident, call India’s national emergency number 112 straight away. The Ministry of Home Affairs describes 112 as the single emergency number under the Emergency Response Support System, though how services are dispatched can vary by state. Keep applying direct pressure while you wait, unless you have been trained to do something different.

Points to bear in mind, based on the manufacturer’s labelling and general first-aid principles:

Follow product-specific instructions. This article does not give dosage, quantity, depth or application steps. Anyone who owns the product should use only the manufacturer’s official instructions for use.
Not for blood vessels. The manufacturer’s warning says not to inject the product or place it into blood vessels, because it may cause embolisation or death.
Allergy question. The label says the product contains a polysaccharide from shrimp shells. It states that allergy studies showed no adverse reactions, which is a manufacturer statement. Anyone with a history of allergy should ask a doctor or pharmacist before relying on the product. Adverse-reaction data beyond the label were not found.
Sterility and storage. The label says sterility is not guaranteed if the package is opened or damaged, and that damaged packs should be discarded. NIT Rourkela reports a three-year shelf life at room temperature. The label also says do not eat and avoid contact with eyes.
Deep, penetrating or arterial bleeding. The manufacturer lists venous and arterial bleeds among intended uses. In real life, these are the injuries most likely to be life-threatening and most in need of trained help. They are not suitable for improvised self-treatment.
Children, pregnancy and blood-thinning medicines. No reliable independent evidence on these groups was found in the sources reviewed. Do not assume the product behaves the same way for everyone.
Infection. Even if a product is described as helping prevent infection, no first-aid product can guarantee it. Wounds still need proper cleaning and professional assessment.

StopBleed vs Traditional Bleeding Control Methods

Hemostatic products sit alongside, not above, established first-aid methods. The 2023 joint position statement from the American College of Surgeons Committee on Trauma, the American College of Emergency Physicians and the National Association of EMS Physicians says direct pressure remains the first choice and controls bleeding in most patients. The Stop the Bleed programme teaches three core steps: pressure, wound packing and tourniquets.

Method	Role	Notes
Direct pressure	First step for most external bleeding	Firm, continuous pressure with a clean cloth or gauze until help arrives.
Pressure dressing	Maintains pressure after initial control	Helps hold a dressing in place; does not replace medical assessment.
Conventional gauze or wound packing	For deep wounds where surface pressure is not enough	Taught in bleeding-control courses; training matters.
Hemostatic products (powders, impregnated gauze, pellets)	Added support alongside pressure where indicated	An earlier American College of Surgeons guideline supports using a topical hemostatic agent with direct pressure in places where a tourniquet cannot be used and pressure alone is not working. Product choice and evidence differ between products.
Tourniquet	Life-threatening limb bleeding when pressure is ineffective	Needs correct equipment and training. Removal is a task for medical professionals.

Different tools serve different situations. Standard first-aid guidance remains the foundation, and a novel product should be seen as an addition to it, not a substitute.

StopBleed and the Importance of First Aid Awareness in India

Technology helps only if people know when and how to act. In many road accidents, the first person at the scene is a bystander, not a trained clinician. Basic bleeding-control knowledge includes recognising dangerous bleeding, calling 112, applying firm pressure, and staying with the injured person until help arrives. Courses based on recognised first-aid and bleeding-control programmes, offered through hospitals and accredited training organisations, build these skills far more reliably than any product alone.

Access to evidence-based trauma care also matters. NIT Rourkela notes that rural and remote areas often lack quick access to advanced care. Technologies like StopBleed are meant to help bridge that gap, but their real-world value will depend on published evidence, regulatory oversight, training and supply across the country.

StopBleed® vs Similarly Named Medicines

Readers searching online may find other products with a similar name. Pharmacy information websites list “Stopbleed” tablets and injections that contain tranexamic acid (500 mg), a prescription antifibrinolytic. Such medicines work from inside the body by slowing the breakdown of clots, and are given on a doctor’s advice. They are not the same thing as Miraqules’ StopBleed®, which is an external, topical hemostatic device applied at the wound site. The two products have different makers, forms and uses. No connection between them was found in the sources reviewed. Never swap one for the other, and never take a tablet or injection for bleeding without medical advice.

Frequently Asked Questions (FAQ)

1. What is StopBleed®?

It is a topical, external hemostatic product made by Miraqules MedSolutions, described by NIT Rourkela as a rapid nano-biopolymer hemostat for bleeding control, available in powder and pellet forms.

2. Who developed StopBleed?

NIT Rourkela says the technology was developed by Professor Devendra Verma and his then research student Sabir Hossain. It was patented by the institute and transferred to Miraqules, which Dr Hossain leads.

3. How does StopBleed hemostatic powder work?

According to the manufacturer and NIT Rourkela, the nanofibrous material absorbs fluid, concentrates clotting components and traps blood cells in a fibre mesh, helping a stable clot and gel-like seal form. These are reported mechanisms, supported mainly by laboratory data on related materials.

4. Is StopBleed an Indian innovation?

Yes, according to NIT Rourkela and the company. The research originated at an Indian institute, and the company has a registered address in Burdwan, West Bengal, and an office in Bengaluru.

5. What are the different StopBleed product formats?

The official website lists StopBleed Powder and StopBleed Pro, which uses a pellet in a pre-filled applicator. A gauze or patch format was not found on the official pages and is not independently verified.

6. Does StopBleed stop bleeding within 30 seconds?

The company’s products page says about 40 seconds, and other pages say under or within a minute. A 30-second claim was not found on the official pages reviewed. The conditions behind these timings are not fully published, so they should not be treated as guaranteed results.

7. Can StopBleed be used for deep wounds?

The manufacturer lists deep wounds and narrow entry wounds as intended uses. Deep or penetrating injuries are, however, medical emergencies that need professional care. A product should never delay a call to 112.

8. Is StopBleed suitable for every type of bleeding?

No. It is intended for external bleeding. It cannot treat internal bleeding, and independent evidence for every patient group and wound type is not available.

9. Does StopBleed replace hospital treatment?

No. The manufacturer’s own instructions advise seeking medical attention when required. Severe bleeding may need surgery, transfusion and other hospital care.

10. Is StopBleed approved in India?

NIT Rourkela and several media outlets reported in February 2026 that CDSCO approved it as a Class C medical device. The licence database was not checked for this article, so the exact licence details are not independently verified.

11. Is StopBleed the same as StopBleed tablets or injections?

No. Tablets and injections sold under similar names contain tranexamic acid and are prescription medicines. Miraqules’ StopBleed® is an external hemostatic product.

12. Where can people find authentic StopBleed product information?

Start with Miraqules’ official website and the NIT Rourkela news page, and ask the company for regulatory documents. Be careful with unofficial sellers and marketplace listings, which may not be accurate.

Conclusion

StopBleed hemostatic powder is an interesting example of Indian biomedical innovation moving from a university laboratory to the regulatory process and early clinical use. The science behind nanofibrous hemostatic materials is plausible and is supported by peer-reviewed laboratory research on related formulations. The CDSCO approval reported in 2026 is a notable milestone.

At the same time, many of the most striking claims, including speed, performance in patients on blood thinners, absence of heat and infection prevention, come from the manufacturer and still lack publicly available independent confirmation. Responsible health communication means saying so clearly. The best outcomes in emergencies still come from simple steps: calling 112, applying firm pressure, learning proper first aid and reaching professional care quickly. New products may add to this chain, but they cannot replace it.

Medical Disclaimer

This article is for general education and information only. It is not medical advice, diagnosis or treatment, and it is not an endorsement or recommendation of any product. NewsWebFit is not the manufacturer, seller or distributor of StopBleed® and has no commercial relationship with Miraqules MedSolutions. Product details, regulatory status and claims may change. Always follow the manufacturer’s official instructions and the advice of a qualified healthcare professional. In any emergency or case of severe bleeding, call 112 immediately.

Scientific Sources and Further Reading

Manufacturer sources describe company claims. They are not independent clinical evidence. Pages were consulted at the time of writing, and some third-party pages could be read only in part.

Miraqules MedSolutions Pvt. Ltd. – Products. https://www.miraqules.com/products/. Supports: product range, about-40-seconds claim, testing statement, label warnings, contact and registered addresses, founder background.
Miraqules MedSolutions Pvt. Ltd. – Stop Bleed Powder. https://www.miraqules.com/stop-bleed-powder/. Supports: manufacturer claims and intended uses for the powder.
Miraqules MedSolutions Pvt. Ltd. – Stop Bleed Pro. https://www.miraqules.com/stop-bleed-pellet/. Supports: pellet and applicator description, narrow-entry-wound use.
Miraqules MedSolutions Pvt. Ltd. – Tech Platform Description. https://www.miraqules.com/tech-platform-description/. Supports: reported fabrication method, absorption and clot-binding mechanism, future applications.
NIT Rourkela – NIT Rourkela Innovation Advances Emergency Trauma Care with CDSCO-Approved StopBleed®. https://www.nitrkl.ac.in/Home/AllNews/?id=10088. Supports: development at NIT Rourkela, technology transfer, CDSCO Class C approval report, patent coverage, animal and first-in-human testing statements, shelf life.
BioSpectrum India – NIT Rourkela’s StopBleed® receives CDSCO approval as Class C medical device (24 February 2026). https://biospectrumindia.com/news/91/27379/nit-rourkelas-stopbleed-receives-cdsco-approval-as-class-c-medical-device.html. Supports: independent trade-media report of the approval.
Deccan Chronicle – Another Feather In NIT Rourkela’s Cap: StopBleed® Advances From Lab To Lifesaving Trauma Care. https://www.deccanchronicle.com/nation/education/another-feather-in-nit-rourkelas-cap-stopbleed-advances-from-lab-to-lifesaving-trauma-care-1939584. Supports: limited deployment in select clinical settings.
YourStory – StopBleed by Miraqules: India’s homegrown innovation to save lives instantly. https://yourstory.com/2025/05/miraqules-stopbleed-india-startup-trauma-care-innovation. Supports: company background and Burdwan origin (business publication; not clinical evidence).
US Patent and Trademark Office record via Google Patents – US12280071B2, Self-assembled nano-fibers as hemostatic agent. https://patents.google.com/patent/US12280071. Supports: inventors, assignee and the chitosan and casein nanofibre composition. Grant date confirmed via Justia Patents.
Hossain S, Mohanty S, Verma D. Polyelectrolyte complex based nanofibrous aggregates for fast hemostasis. Materials Today Communications, vol. 27, 2021, 102364. https://doi.org/10.1016/j.mtcomm.2021.102364. Supports: laboratory and in-vivo research on chitosan and alginate nanofibrous aggregates.
Mishra B, Hossain S, Mohanty S, Gupta MK, Verma D. Fast acting hemostatic agent based on self-assembled hybrid nanofibers from chitosan and casein. International Journal of Biological Macromolecules, vol. 185, 2021, pp. 525–534. Listed in Professor Verma’s publications at https://www.nitrkl.ac.in/docs/Faculty/CV/1141111.pdf; summary at https://www.peeref.com/works/4763342. Supports: research on chitosan and casein nanofibres and clotting speed.
StatPearls / NCBI Bookshelf – Physiology, Hemostasis. https://www.ncbi.nlm.nih.gov/books/NBK545263/. Supports: stages of natural hemostasis, platelets and fibrin.
American College of Surgeons Committee on Trauma, American College of Emergency Physicians, National Association of EMS Physicians – Prehospital Hemorrhage Control and Treatment by Clinicians: A Joint Position Statement (March 2023), copy hosted at https://www.handtevy.com/wp-content/uploads/2024/12/Prehospital-Hemorrhage-Control-and-Treatment-by-Clinicians-A-Joint-Position-Statement-March-2023.pdf. Supports: direct pressure as first choice, wound packing, role of tourniquets.
UPMC Trauma Rounds – Stop the Bleed! (reprint of the American College of Surgeons Committee on Trauma prehospital external hemorrhage guideline). https://www.upmc.com/-/media/upmc/healthcare-professionals/departments/emergency-medicine/documents/trauma-rounds-spring-final.pdf. Supports: topical hemostatic agents used together with direct pressure when tourniquets cannot be applied.
Ministry of Home Affairs, Government of India – Emergency Response Support System (ERSS). https://www.mha.gov.in/en/commoncontent/emergency-response-support-system-erss. Supports: 112 as India’s single emergency number.
myUpchar – Stopbleed Tablet (tranexamic acid). https://myupchar.com/en/medicine/stopbleed-p37095742. Supports: existence of similarly named prescription tranexamic acid products (pharmacy information site; not a regulator).

Published by NewsWebFit | Health, Medical Science & Wellness Information.

StopBleed Hemostatic Powder: India’s Bleeding Control Tech